Superoxide Dismutase Skin Spray for the Prevention of Acute Radiation Dermatitis in Head and Neck Cancer
Superoxide Dismutase Skin Spray for Reducing Acute Radiation Dermatitis in Patients With Head and Neck Cancer Undergoing Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Xingchen Peng
- Telefonnummer: +86 18980606753
- E-post: pxx2014@163.com
Studer Kontakt Backup
- Navn: Yu Min
- Telefonnummer: 13108175138
Studiesteder
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- Sichuan University West China Hospital
-
Ta kontakt med:
- Xingchen Peng
- Telefonnummer: +86 18980606753
- E-post: pxx2014@163.com
-
Ta kontakt med:
- Yu Min
- Telefonnummer: 13108175138
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Histologically confirmed malignant tumors of the head and neck without distant metastasis.
- Scheduled to undergo either postoperative adjuvant radiotherapy or definitive radiotherapy, with or without concurrent chemotherapy.
- Age 18-80 years at the time of consent.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Signed informed consent form.
- Adequate cognitive and reading abilities to complete the questionnaire.
Exclusion Criteria:
- Pre-existing skin disease or open wounds in the irradiation field.
- Have a history of head and neck radiotherapy.
- Autoimmune or connective tissue disorders affecting skin.
- Known allergy to any component of study formulations.
- Any condition that, in the investigator's judgment, would interfere with study participation or outcome assessment.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo excipient spray
A placebo spray consisting of the excipient formulation without superoxide dismutase, which is the same as the experimental group in appearance.
|
Patients are instructed to apply a placebo excipient spray without superoxide dismutase evenly to the entire radiotherapy-treated skin area, approximately 3 sprays per application, five times daily, following the same schedule as the experimental group.
Treatment is initiated at the start of radiotherapy and continued until the occurrence of grade ≥2 radiation dermatitis or up to one week after completion of radiotherapy, whichever occurs first.
Patients are instructed to keep the irradiated skin clean and dry and to avoid the use of other topical agents in the treatment area.
|
|
Eksperimentell: Superoxide dismutase containing skin spray
A topical skin spray containing superoxide dismutase
|
Patients are instructed to apply a topical superoxide dismutase-containing spray evenly to the entire radiotherapy-treated skin area, approximately 3 sprays per application, five times daily.
Treatment is initiated at the start of radiotherapy and continued until the occurrence of grade ≥2 radiation dermatitis or up to one week after completion of radiotherapy, whichever occurs first.
Patients are instructed to keep the irradiated skin clean and dry and to avoid the use of other topical agents in the treatment area.
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of grade ≥ 2 ARD
Tidsramme: From the start of radiotherapy to 4 weeks after completion of radiotherapy
|
Patients are assessed weekly for radiation dermatitis by an experienced radiation oncology nurse according to the Radiation Therapy Oncology Group (RTOG) scale.
The RTOG scale categorizes acute skin toxicity into grades 0-4, with the higher the grade the more severe the patient's acute radiation dermatitis.
Grade 0 means no change over baseline.
Grade 1 means follicular, faint, or dull erythema; epilation, dry desquamation, or decrease in sweating.
Grade 2 means tender, bright erythema; patchy, moist desquamation or moderate edema.
Grade 3 means confluent, moist desquamation other than skin folds; pitting edema.
Grade 4 means ulceration, hemorrhage, necrosis.
|
From the start of radiotherapy to 4 weeks after completion of radiotherapy
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to onset of grade ≥ 2 ARD between the two arms.
Tidsramme: From the start of radiotherapy to 4 weeks after completion of radiotherapy.
|
Time from the first day of radiotherapy to the first determination of grade 2 or higher radiation dermatitis.
|
From the start of radiotherapy to 4 weeks after completion of radiotherapy.
|
|
Duration of grade ≥ 2 ARD between the two arms.
Tidsramme: From the start of radiotherapy to 4 weeks after completion of radiotherapy.
|
The first determination of grade 2 or higher radiation dermatitis to the first instance of grade 1 or 0 radiation dermatitis, without a subsequent instance of grade 2 or higher radiation dermatitis.
Patients without observed grade 2 or higher radiation dermatitis were assigned a duration of 0 days.
|
From the start of radiotherapy to 4 weeks after completion of radiotherapy.
|
|
Maximum dermatitis grade
Tidsramme: From the start of radiotherapy to 4 weeks after completion of radiotherapy.
|
The maximum grade of RTOG skin toxicity between 0 and 4.
|
From the start of radiotherapy to 4 weeks after completion of radiotherapy.
|
|
Grade ≥3 radiation dermatitis incidence
Tidsramme: From the start of radiotherapy to 4 weeks after completion of radiotherapy.
|
Patients are assessed weekly for radiation dermatitis by an experienced radiation oncology nurse according to the Radiation Therapy Oncology Group (RTOG) scale.
The RTOG scale categorizes acute skin toxicity into grades 0-4, with the higher the grade the more severe the patient's acute radiation dermatitis.
Grade 0 means no change over baseline.
Grade 1 means follicular, faint, or dull erythema; epilation, dry desquamation, or decrease in sweating.
Grade 2 means tender, bright erythema; patchy, moist desquamation or moderate edema.
Grade 3 means confluent, moist desquamation other than skin folds; pitting edema.
Grade 4 means ulceration, hemorrhage, necrosis.
|
From the start of radiotherapy to 4 weeks after completion of radiotherapy.
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Generell helsetilstand og kjerneområder for livskvalitet
Tidsramme: Den totale evalueringsperioden er omtrent 14 til 14,5 uker.
|
Europeisk organisasjon for forskning og behandling av kreft kvalitet på liv-spørreskjema kjernen 30 (EORTC QLQ-C30) Dette instrumentet er et pasientrapportert utfallsmål (PRO) med 30 elementer designet for å evaluere kjerneaspekter av helserelatert livskvalitet hos kreftpasienter, inkludert 5 funksjonelle skalaer (fysisk, rolle, kognitiv, emosjonell, sosial), 3 symptomer-skalaer (tretthet, smerte, kvalme og oppkast), en global helsetilstand/livskvalitet-skala, og 6 enkeltelements symptommålinger.
Skårer blir lineært transformert til et område på 0-100.
For de funksjonelle skalaene og den globale helsetilstand-skalaen indikerer høyere skårer bedre funksjonsnivåer eller livskvalitet; for symptomer-skalaene/elementene indikerer høyere skårer større symptombyrde.
|
Den totale evalueringsperioden er omtrent 14 til 14,5 uker.
|
|
Spesifikke symptomer på hode- og halskreft
Tidsramme: Den totale evalueringsperioden er omtrent 14 til 14,5 uker.
|
EORTC QLQ-H&N35 er et pasientrapportert resultatmålingsverktøy (PRO) spesielt utviklet for å vurdere sykdomsrelaterte symptomer og behandlingsrelaterte bivirkninger hos pasienter med hode- og halskreft.
Det består av 35 elementer, organisert i syv flerelement-skalaer (smerte, svelging, sanser, tale, sosial spising, sosial kontakt og seksualitet) og elleve enkeltelement-mål (som tannproblemer, problemer med å åpne munnen, klissete spytt, hosting, etc.).
Alle skala- og enkeltelement-resultater transformeres lineært til en 0-100 skala ved hjelp av en standardisert poengsettingsalgoritme.
Tolkning av resultater: For alle skalaer og enkeltelementer representerer høyere poeng mer alvorlige symptomer eller større symptombyrde.
|
Den totale evalueringsperioden er omtrent 14 til 14,5 uker.
|
|
Radiotherapy interruption rate
Tidsramme: Up to 8 weeks (from initiation to completion of radiotherapy)
|
Radiotherapy interruption is defined as an unplanned prolongation of the radiotherapy schedule resulting in a delay of ≥5 days compared with the planned treatment schedule, excluding scheduled breaks.
|
Up to 8 weeks (from initiation to completion of radiotherapy)
|
|
Patient-reported skin symptoms from the Skindex-16
Tidsramme: From 1 week before radiotherapy to 4 weeks after completion of radiotherapy.
|
The Skindex-16 is a commonly used tool to measure the effect of skin diseases on the skin-related QoL of patients.
Skindex-16 consists of domain scores that assess how symptoms, emotions, and functioning from the skin issue affect the QOL of patients with acne.
The overall score averages the 3 domain scores, all of which are normalized to a 0 to 100 scale, where 0 indicates that their skin condition has no impact on QOL and 100 represents maximal impact on QOL for the worse.
|
From 1 week before radiotherapy to 4 weeks after completion of radiotherapy.
|
|
Skin microbiome composition and diversity
Tidsramme: Baseline and end of radiotherapy (approximately 8 weeks after radiotherapy initiation)
|
Skin microbiome composition and diversity will be assessed as an exploratory endpoint using 16S rRNA gene sequencing.
Skin swab samples will be collected from the irradiated skin area at baseline (before radiotherapy initiation) and at completion of radiotherapy.
|
Baseline and end of radiotherapy (approximately 8 weeks after radiotherapy initiation)
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Tidsramme: From 1 week before radiotherapy to 4 weeks after completion of radiotherapy.
|
Common Terminology Criteria for Adverse Events (CTCAE) 5.0 version.
|
From 1 week before radiotherapy to 4 weeks after completion of radiotherapy.
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Xingchen Peng, study principal investigator
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- 2026(819)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .